证券代码：603987 证券简称：康德莱 公告编号：2025-021 本次权益变动属于股份协议转让，不涉及要约收购，不会导致公司控股 股东及实际控制人发生变化，不会对公司持续稳定经营产生不利影响。 本次协议转让尚需上海证券交易所进行合规性确认，并在中国证券登记 结算有限责任公司上海分公司（以下简称"中国结算上海分公司"）办理股份过 户登记手续，最终实施结果尚存在不确定性，敬请广大投资者注意投资风险。 一、协议转让概述 （一）本次协议转让的基本情况 1、本次协议转让情况 上海康德莱企业发展集团股份有限公司 关于公司控股股东协议转让股份引入战略投资者暨权益变动的 提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为了进一步深化康德莱集团的战略布局，促进实现各方协同共赢的战略 目标，上海康德莱企业发展集团股份有限公司（以下简称"公司"）控股股东上 海康德莱控股集团有限公司（以下简称"康德莱控股集团"）与长沙械字号医疗 投资有限公司（以下简称"长沙械字号"）于 2025 年 9 月 1 日签署了《股 ...

信息披露义务人：上海康德莱控股集团有限公司 经营场所：上海市嘉定区嘉峪关路 379 弄 11 号 1 层 通讯地址：上海市嘉定区嘉峪关路 379 弄 11 号 1 层 权益变动性质：股份减少（协议转让） 签署日期：2025 年 9 月 2 日 1 上海康德莱企业发展集团股份有限公司 简式权益变动报告书 上市公司名称：上海康德莱企业发展集团股份有限公司 股票上市地点：上海证券交易所 股票简称：康德莱 股票代码：603987 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司收购管理办法》（以下简称"《收购管理办 法》"）、《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变 动报告书》（以下简称"《准则 15 号》"）及其他相关的法律、法规和规范 性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《收购管理办法》《准则 15 号》的规定，本报告书 已全面披露信息披露义务人在上海康德莱企业发展集团股份有限公司中拥有 权益的股份变动情况。 四、截至本报告书签署之日，除本报告书披露的持股信息外，信息披露 义 ...

Group 1 - The core point of the article is that Kangdelai (603987) announced a share transfer agreement with Changsha Medical Investment Co., Ltd., where the controlling shareholder will transfer 21.8395 million shares, representing 5% of the total share capital, at a price of 10.81 yuan per share, totaling 236 million yuan [1] - The share transfer aims to deepen the strategic layout of Kangdelai Group and is expected to enhance the company's governance and optimize its equity structure [1] - The strategic implementation is anticipated to provide the company with industrial and resource synergies from the strategic partner, expanding its development space in the consumer healthcare sector [1]

Market Performance - The medical device sector increased by 1.87% on September 1, with Yirui Biological leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Device Sector - Yirui Biological (300942) closed at 13.82, up 13.56% with a trading volume of 263,400 shares and a transaction value of 350 million [1] - Jimin Health (603222) closed at 12.67, up 9.98% with a trading volume of 1,050,500 shares [1] - Hualan Biological (301093) closed at 37.16, up 9.55% with a trading volume of 123,900 shares [1] - Huatai Medical (688617) closed at 305.49, up 7.43% with a trading volume of 30,100 shares [1] - United Imaging Healthcare (688271) closed at 152.10, up 7.26% with a trading volume of 147,200 shares [1] Top Losers in Medical Device Sector - Toukeng Life (300642) closed at 28.50, down 7.71% with a trading volume of 234,300 shares [2] - Blue Sail Medical (002382) closed at 5.99, down 3.07% with a trading volume of 288,400 shares [2] - Wuzhou Medical (301234) closed at 43.30, down 2.48% with a trading volume of 20,800 shares [2] Capital Flow Analysis - The medical device sector saw a net inflow of 68.08 million from institutional investors, while retail investors contributed a net inflow of 14.9 million [2] - The sector experienced a net outflow of 217 million from speculative funds [2] Individual Stock Capital Flow - Mindray Medical (300760) had a net inflow of 90.24 million from institutional investors, while it faced a net outflow of 128 million from speculative funds [3] - United Imaging Healthcare (688271) saw a net inflow of 87.93 million from institutional investors, with a net outflow of 130 million from speculative funds [3] - Jimin Health (603222) experienced a net inflow of 79.82 million from institutional investors, but a net outflow of 49.23 million from speculative funds [3]

数据显示，招商基金旗下1只基金位居康德莱十大流通股东。招商量化精选股票发起式A（001917）二 季度减持251.36万股，持有股数327.11万股，占流通股的比例为0.75%。根据测算，今日浮盈赚取约 150.47万元。 招商量化精选股票发起式A（001917）成立日期2016年3月15日，最新规模27.65亿。今年以来收益 37.35%，同类排名744/4223；近一年收益73.66%，同类排名928/3780；成立以来收益268.66%。 招商量化精选股票发起式A（001917）基金经理为王平。 9月1日，康德莱涨5.06%，截至发稿，报9.55元/股，成交1.94亿元，换手率4.76%，总市值41.71亿元。 资料显示，上海康德莱企业发展集团股份有限公司位于上海市嘉定区高潮路658号，成立日期1998年7月 1日，上市日期2016年11月21日，公司主营业务涉及从事医用穿刺针、医用输注器械、介入器械等医疗 器械的研发、生产、销售和服务。主营业务收入构成为：穿刺护理类63.43%，标本采集类13.96%，其 他类13.23%，医美类5.30%，穿刺介入类4.08%。 从康德莱十大流通股东角度 风险提示： ...

9月1日，康德莱涨5.06%，截至发稿，报9.55元/股，成交1.93亿元，换手率4.76%，总市值41.71亿元。 资料显示，上海康德莱企业发展集团股份有限公司位于上海市嘉定区高潮路658号，成立日期1998年7月 1日，上市日期2016年11月21日，公司主营业务涉及从事医用穿刺针、医用输注器械、介入器械等医疗 器械的研发、生产、销售和服务。主营业务收入构成为：穿刺护理类63.43%，标本采集类13.96%，其 他类13.23%，医美类5.30%，穿刺介入类4.08%。 从康德莱十大流通股东角度 数据显示，国寿安保基金旗下1只基金位居康德莱十大流通股东。国寿安保智慧生活股票A（001672） 二季度持有股数421万股，持股数量与上期相比不变，占流通股的比例为0.96%。根据测算，今日浮盈 赚取约193.66万元。 国寿安保智慧生活股票A（001672）成立日期2015年9月1日，最新规模18.28亿。今年以来收益 38.43%，同类排名687/4223；近一年收益86.88%，同类排名608/3780；成立以来收益225.05%。 国寿安保智慧生活股票A（001672）基金经理为张琦。 截至发稿，张琦累计 ...

Summary of the Conference Call for 康德莱 Company Overview - 康德莱 reported a revenue of 1.12 billion yuan for the first half of 2025, representing a year-on-year growth of 19.4% [2][3] - The net profit attributable to shareholders was 125 million yuan, with a growth of 18.94% year-on-year [3] - The company achieved a basic earnings per share of 0.28 yuan [2][3] Market Performance Domestic Market - Domestic revenue reached 720 million yuan, contributing significantly to overall performance [2][8] - The company is focusing on winning bids in the domestic market by leveraging its medical equipment [7][11] International Market - International revenue was approximately 400 million yuan, with notable growth in Asia and Europe [2][4] - The company is optimistic about its international market development, particularly in South America, Africa, and Southeast Asia [9][20] Strategic Initiatives - 康德莱 is actively expanding into non-medical fields, with a significant increase in sales from aesthetic medical products [2][6] - The pre-filled drug packaging products saw a sales increase of over 50% year-on-year [2][6] - The company is transitioning from an agency model to a distribution model to better respond to centralized procurement policies [12] Product Development - The company has optimized its product matrix, focusing on high-margin products such as blood collection needles and anesthetic insulin series [2][8][15] - The penetration of the puncture needle series has filled a domestic market gap, supporting gross margin and net profit stability [2][6] Cost Management and Automation - 康德莱 has invested heavily in smart manufacturing, achieving 80% automation in its medical device production [5][16] - The company maintains a competitive cost structure due to its full industry chain advantage and strategic manufacturing base distribution [15] Challenges and Responses - The company is addressing challenges from tariffs and centralized procurement by focusing on non-US markets and optimizing customer management [7][18] - Despite a projected 10% decline in the US market, 康德莱 remains committed to exploring non-US markets for growth [18] Future Outlook - The company expects to maintain stable gross and net profit margins throughout 2025, with a focus on high-value-added products [18] - 康德莱 aims for a balanced revenue structure, targeting a 50% sales ratio in both domestic and international markets [20] Additional Insights - The company has received approximately 700 effective customer inquiries through its online promotion efforts, resulting in over 30 orders [14] - The strategic relocation of its Guangxi base is expected to enhance production capacity in the second half of the year [10][17] This summary encapsulates the key points from the conference call, highlighting 康德莱's performance, strategic initiatives, market dynamics, and future outlook.

Core Insights - 康德莱 (603987) reported a slight increase in total revenue and a significant rise in net profit for the first half of 2025, indicating improved profitability and operational efficiency [1] Financial Performance - Total revenue for H1 2025 reached 1.125 billion yuan, a year-on-year increase of 0.17% [1] - Net profit attributable to shareholders was 125 million yuan, up 18.94% year-on-year [1] - In Q2 2025, total revenue was 577 million yuan, reflecting a 4.29% increase compared to the same quarter last year [1] - Q2 net profit attributable to shareholders was 64.43 million yuan, showing a substantial increase of 44.29% year-on-year [1] - Gross margin improved to 32.66%, an increase of 8.18% year-on-year, while net margin rose to 12.18%, up 17.85% year-on-year [1] Cost Structure - Total selling, administrative, and financial expenses amounted to 182 million yuan, accounting for 16.18% of revenue, which is a slight increase of 1.43% year-on-year [1] - The decrease in operating costs was noted at -3.37%, attributed to optimized product structure [1] - Selling expenses decreased by 7.7% due to optimized sales models [2] - Administrative expenses increased by 11.69% due to rising labor costs [3] - Financial expenses surged by 36.12% due to changes in financing structure [4] Cash Flow and Assets - Operating cash flow per share was 0.17 yuan, down 14.43% year-on-year [1] - The company reported a net cash flow from investing activities increase of 27.94%, influenced by prior year investment payments [4] - Net cash flow from financing activities increased by 77.56%, impacted by prior year loan repayments [5] - Cash and cash equivalents increased to 330 million yuan, a 3.06% rise year-on-year [1] - Accounts receivable rose to 1 billion yuan, a 6.22% increase year-on-year [1] Return on Investment - The company's return on invested capital (ROIC) for the previous year was 7.04%, indicating average capital returns [6] - Historical data shows a median ROIC of 10.62% since the company went public [6] - The company's business model relies heavily on marketing-driven performance, necessitating further analysis of underlying drivers [7]

Market Overview - The Shanghai Composite Index fell by 0.39% on August 26, with 17 sectors rising, led by Agriculture, Forestry, Animal Husbandry, and Fishery (up 2.62%) and Beauty and Personal Care (up 2.04%) [1] - The sectors that experienced the largest declines were Pharmaceutical and Biological (down 1.09%) and Non-Bank Financials (down 1.06%) [1] - Overall, there was a net outflow of 68.855 billion yuan in the main funds across the two markets, with only two sectors seeing net inflows: Beauty and Personal Care (net inflow of 276 million yuan) and Agriculture, Forestry, Animal Husbandry, and Fishery (net inflow of 257 million yuan) [1] Pharmaceutical and Biological Sector - The Pharmaceutical and Biological sector saw a decline of 1.09%, with a net outflow of 8.254 billion yuan in main funds [2] - Out of 474 stocks in this sector, 151 stocks rose, 3 stocks hit the daily limit, and 307 stocks fell [2] - The stocks with the highest net inflows included Kangdelai (net inflow of 112 million yuan), Wanbangde (net inflow of 111 million yuan), and Anke Bio (net inflow of 80.217 million yuan) [2] - The stocks with the largest net outflows included Hanyu Pharmaceutical (net outflow of 766 million yuan), WuXi AppTec (net outflow of 706 million yuan), and Sihai Medical (net outflow of 408 million yuan) [2] Fund Flow Analysis Inflow Leaders - Kangdelai: +10.05% with a turnover rate of 10.15% and main fund flow of 111.545 million yuan [3] - Wanbangde: +9.97% with a turnover rate of 8.58% and main fund flow of 110.956 million yuan [3] - Anke Bio: -0.25% with a turnover rate of 9.03% and main fund flow of 80.217 million yuan [3] Outflow Leaders - Hanyu Pharmaceutical: -5.94% with a turnover rate of 16.12% and main fund flow of -766.138 million yuan [4] - WuXi AppTec: -3.18% with a turnover rate of 2.70% and main fund flow of -705.940 million yuan [4] - Sihai Medical: +4.99% with a turnover rate of 37.04% and main fund flow of -407.547 million yuan [4]

上交所公开信息显示，当日该股因日涨幅偏离值达10.43%上榜，营业部席位合计净买入4227.45万元。 康德莱8月26日交易公开信息 康德莱(603987)今日涨停，全天换手率10.15%，成交额4.25亿元，振幅5.01%。龙虎榜数据显示，营业 部席位合计净买入4227.45万元。 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 华泰证券股份有限公司总部 | 1987.74 | | | 买二 | 国泰海通证券股份有限公司总部 | 1495.88 | | | 买三 | 华宝证券股份有限公司上海东大名路证券营业部 | 1355.65 | | | 买四 | 中国国际金融股份有限公司北京建国门外大街证券营业 部 | 1320.18 | | | 买五 | 开源证券股份有限公司西安西大街证券营业部 | 1076.10 | | | 卖一 | 西部证券股份有限公司西安雁塔路证券营业部 | | 997.36 | | 卖二 | 申万宏源证券有限公司武汉静安路证券营业部 | | 598.97 | | 卖三 ...